Prophylaxis with enoxaparin for prevention of venous thromboembolism after lung transplantation: a retrospective study

Venous thromboembolism (VTE) is a frequent complication after solid organ transplantation (SOT) and, specifically, after lung transplantation (LT). The objectives of this study were to evaluate prophylaxis with enoxaparin and to describe risk factors for VTE after LT. We retrospectively reviewed the...

Descripción completa

Detalles Bibliográficos
Autores: Saez-Gimenez, B, Berastegui, C, Sintes, H, Perez-Miranda, J, Figueredo, A, Lopez Meseguer, M, Monforte, V, Bravo, C, Santamaria, A, Ramon, MA, Gomez-Olles, S, Roman, A
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2017
País:España
Institución:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Repositorio:r-FISABIO. Repositorio Institucional de Producción Científica
OAI Identifier:oai:fisabio.fundanetsuite.com:p13227
Acceso en línea:https://fisabio.portalinvestigacion.com/publicaciones/13227
Access Level:acceso abierto
Palabra clave:lung transplantation
venous thromboembolism
id ES_f4a2a879f27896ccedf2eb350e691bc8
oai_identifier_str oai:fisabio.fundanetsuite.com:p13227
network_acronym_str ES
network_name_str España
repository_id_str
spelling Prophylaxis with enoxaparin for prevention of venous thromboembolism after lung transplantation: a retrospective studySaez-Gimenez, BBerastegui, CSintes, HPerez-Miranda, JFigueredo, ALopez Meseguer, MMonforte, VBravo, CSantamaria, ARamon, MAGomez-Olles, SRoman, Alung transplantationvenous thromboembolismVenous thromboembolism (VTE) is a frequent complication after solid organ transplantation (SOT) and, specifically, after lung transplantation (LT). The objectives of this study were to evaluate prophylaxis with enoxaparin and to describe risk factors for VTE after LT. We retrospectively reviewed the clinical records of 333 patients who underwent LT in our institution between 2009 and 2014. We compared two consecutive cohorts: one that received enoxaparin only during post-transplant hospital admissions and a second cohort that received 90-day extended prophylaxis with enoxaparin. Cumulative incidence function for competing risk analysis was used to determine incidence of VTE during the first year after transplantation. Risk factors were analyzed using a Cox proportional hazards regression model. The cumulative incidence of VTE was 15.3% (95% CI: 11.6-19.4). Median time from transplant to the event was 40 (p25-p75, 14-112) days. Ninety-day extended prophylaxis did not reduce the incidence of VTE. In this study, the risk factors associated with VTE were male gender and interstitial lung disease. VTE is a major complication after LT, and 90-day extended prophylaxis was not able to prevent it. Large, multicenter, randomized clinical trials should be performed to define the best strategy for preventing VTE.FRONTIERS MEDIA SA2017info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fisabio.portalinvestigacion.com/publicaciones/13227TRANSPLANT INTERNATIONALISSN: 09340874ISSNe: 14322277reponame:r-FISABIO. Repositorio Institucional de Producción Científicainstname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)Inglésinfo:eu-repo/semantics/openAccessoai:fisabio.fundanetsuite.com:p132272026-06-11T12:45:17Z
dc.title.none.fl_str_mv Prophylaxis with enoxaparin for prevention of venous thromboembolism after lung transplantation: a retrospective study
title Prophylaxis with enoxaparin for prevention of venous thromboembolism after lung transplantation: a retrospective study
spellingShingle Prophylaxis with enoxaparin for prevention of venous thromboembolism after lung transplantation: a retrospective study
Saez-Gimenez, B
lung transplantation
venous thromboembolism
title_short Prophylaxis with enoxaparin for prevention of venous thromboembolism after lung transplantation: a retrospective study
title_full Prophylaxis with enoxaparin for prevention of venous thromboembolism after lung transplantation: a retrospective study
title_fullStr Prophylaxis with enoxaparin for prevention of venous thromboembolism after lung transplantation: a retrospective study
title_full_unstemmed Prophylaxis with enoxaparin for prevention of venous thromboembolism after lung transplantation: a retrospective study
title_sort Prophylaxis with enoxaparin for prevention of venous thromboembolism after lung transplantation: a retrospective study
dc.creator.none.fl_str_mv Saez-Gimenez, B
Berastegui, C
Sintes, H
Perez-Miranda, J
Figueredo, A
Lopez Meseguer, M
Monforte, V
Bravo, C
Santamaria, A
Ramon, MA
Gomez-Olles, S
Roman, A
author Saez-Gimenez, B
author_facet Saez-Gimenez, B
Berastegui, C
Sintes, H
Perez-Miranda, J
Figueredo, A
Lopez Meseguer, M
Monforte, V
Bravo, C
Santamaria, A
Ramon, MA
Gomez-Olles, S
Roman, A
author_role author
author2 Berastegui, C
Sintes, H
Perez-Miranda, J
Figueredo, A
Lopez Meseguer, M
Monforte, V
Bravo, C
Santamaria, A
Ramon, MA
Gomez-Olles, S
Roman, A
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv lung transplantation
venous thromboembolism
topic lung transplantation
venous thromboembolism
description Venous thromboembolism (VTE) is a frequent complication after solid organ transplantation (SOT) and, specifically, after lung transplantation (LT). The objectives of this study were to evaluate prophylaxis with enoxaparin and to describe risk factors for VTE after LT. We retrospectively reviewed the clinical records of 333 patients who underwent LT in our institution between 2009 and 2014. We compared two consecutive cohorts: one that received enoxaparin only during post-transplant hospital admissions and a second cohort that received 90-day extended prophylaxis with enoxaparin. Cumulative incidence function for competing risk analysis was used to determine incidence of VTE during the first year after transplantation. Risk factors were analyzed using a Cox proportional hazards regression model. The cumulative incidence of VTE was 15.3% (95% CI: 11.6-19.4). Median time from transplant to the event was 40 (p25-p75, 14-112) days. Ninety-day extended prophylaxis did not reduce the incidence of VTE. In this study, the risk factors associated with VTE were male gender and interstitial lung disease. VTE is a major complication after LT, and 90-day extended prophylaxis was not able to prevent it. Large, multicenter, randomized clinical trials should be performed to define the best strategy for preventing VTE.
publishDate 2017
dc.date.none.fl_str_mv 2017
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fisabio.portalinvestigacion.com/publicaciones/13227
url https://fisabio.portalinvestigacion.com/publicaciones/13227
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv FRONTIERS MEDIA SA
publisher.none.fl_str_mv FRONTIERS MEDIA SA
dc.source.none.fl_str_mv TRANSPLANT INTERNATIONAL
ISSN: 09340874
ISSNe: 14322277
reponame:r-FISABIO. Repositorio Institucional de Producción Científica
instname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
instname_str Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
reponame_str r-FISABIO. Repositorio Institucional de Producción Científica
collection r-FISABIO. Repositorio Institucional de Producción Científica
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869424490254958592
score 15,812429

Similares en LA Referencia